[go: up one dir, main page]

AU2003270876A8 - Anti-hla assay and methods - Google Patents

Anti-hla assay and methods

Info

Publication number
AU2003270876A8
AU2003270876A8 AU2003270876A AU2003270876A AU2003270876A8 AU 2003270876 A8 AU2003270876 A8 AU 2003270876A8 AU 2003270876 A AU2003270876 A AU 2003270876A AU 2003270876 A AU2003270876 A AU 2003270876A AU 2003270876 A8 AU2003270876 A8 AU 2003270876A8
Authority
AU
Australia
Prior art keywords
methods
hla assay
hla
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003270876A
Other versions
AU2003270876A1 (en
Inventor
Rod Vangundy
Christopher Giberson
Rico Buchli
William H Hildebrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/337,161 external-priority patent/US20060276629A9/en
Priority claimed from PCT/US2003/000243 external-priority patent/WO2003057852A2/en
Application filed by Individual filed Critical Individual
Publication of AU2003270876A1 publication Critical patent/AU2003270876A1/en
Publication of AU2003270876A8 publication Critical patent/AU2003270876A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2003270876A 2002-09-24 2003-09-24 Anti-hla assay and methods Abandoned AU2003270876A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41384202P 2002-09-24 2002-09-24
US60/413,842 2002-09-24
AU2003202892 2003-01-02
US10/337,161 US20060276629A9 (en) 1999-12-17 2003-01-02 Purification and characterization of soluble human HLA proteins
US10/337,161 2003-01-02
PCT/US2003/000243 WO2003057852A2 (en) 2001-12-18 2003-01-02 Purification and characterization of hla proteins
PCT/US2003/030096 WO2004029280A2 (en) 2002-09-24 2003-09-24 Anti-hla assay and methods

Publications (2)

Publication Number Publication Date
AU2003270876A1 AU2003270876A1 (en) 2004-04-19
AU2003270876A8 true AU2003270876A8 (en) 2004-04-19

Family

ID=32684708

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003270876A Abandoned AU2003270876A1 (en) 2002-09-24 2003-09-24 Anti-hla assay and methods

Country Status (2)

Country Link
AU (1) AU2003270876A1 (en)
WO (1) WO2004029280A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100095441A (en) 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 Modified recombinant factor viii and von willebrand factor and methods of use
EP2536751B1 (en) * 2010-02-17 2018-09-12 One Lambda, Inc. Methods of making compositions useful for the detection of antibodies to native human leukocyte antigen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT814838E (en) * 1995-03-08 2003-09-30 Scripps Research Inst ANTIGEN PRESENTATION SYSTEM AND T-CELL ACTIVATION

Also Published As

Publication number Publication date
WO2004029280A2 (en) 2004-04-08
AU2003270876A1 (en) 2004-04-19
WO2004029280A3 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
IL225633A0 (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
EP1551447A4 (en) Anti-addl antibodies and uses thereof
AU2003299778A8 (en) Antibodies against gpr64 and uses thereof
AU2003243736A8 (en) Improved assay systems and components
EP1539941A4 (en) Adzymes and uses thereof
SI2368907T1 (en) Anti-Abeta antibodies and their use
AU2003296369A8 (en) Imminoamines and preparation thereof
GB0111218D0 (en) Assays methods and means
IL172510A0 (en) Antibodies and uses thereof
IL166063A0 (en) Antibodies and uses thereof
IL165112A0 (en) Variant integrinpolypeptides and thereof
GB0320590D0 (en) Fixing means and methods
AU2003231827A8 (en) Pseudo-tissues and uses thereof
GB2400659B (en) Assay methods and materials
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003270876A8 (en) Anti-hla assay and methods
GB0223960D0 (en) Assay methods
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
AU2003216442A8 (en) Enkurin and uses thereof
GB0202565D0 (en) Assay methods and means
GB0107123D0 (en) Assay methods and means
GB0227080D0 (en) Antibodies and uses thereof
GB0222837D0 (en) Assay device and method
GB0223111D0 (en) Assay device and method
GB0106319D0 (en) Assays methods and means

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase